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The interaction of chemotactic peptide (e.g., fMet-Leu-Phe)-grafted liposomes with macrophages is noted to
be rapid and specific. At a grafted peptide concentration of 100 nmol, internalization of the peptide-grafted
liposomes by the macrophages is found to reach equilibrium in 30 min. The peptide alone and the peptide-
grafted empty liposomes are found to show moderate antileishmanial activity in vitro. Primaquine, which is
known to generate O2
2 in phagocytic cells, showed leishmanicidal properties when it was tested in vitro against
parasite-infected macrophages over a certain range of concentrations. It showed much better efficacy against
experimental leishmaniasis when it was used in the fMet-Leu-Phe-grafted liposomal form in comparison with
its efficacy when it was either in the free form or encapsulated in ungrafted liposomes. The conventional toxicity
parameters (e.g., blood pathology and tissue histology-specific enzyme levels related to normal liver function)
are found to be very close to normal when fMet-Leu-Phe-grafted liposomal primaquine is used. The biode-
gradabilities of both the drug and the delivery systems are also found to be very satisfactory. Thus, this delivery
system may have possible applications for the treatment of leishmaniasis as well as other macrophage-
associated disorders.
Macrophages are chemotactically responsive cells that are of
central importance to both the recognition and the effector
limbs of the immune response. Chemotaxis, by definition, is
the directed movement of cells along a chemical gradient, and
it appears to be an important mechanism by which inflamma-
tory cells accumulate at local sites (18, 19). The chemotactic
agonists stimulate the macrophages and induce the respiratory
burst (2, 3), resulting in the activation of NADPH oxidase,
which catalyzes the conversion of molecular oxygen to super-
oxide anion (O2
2). This O2
2 is the precursor of a series of
microbicidal products (6). This activation is initiated by the
binding of a chemotactic agonist to its receptor. It is prevented
by the antagonist and is interrupted by agonist displacement,
indicating that the agonist receptor complex must persist (3).
We have developed a delivery system using one such chemo-
tactic agonist, i.e., one peptide (N-formyl-methionine-leucine-
phenylalanine [fMLP]) that has the chemoattracting properties
for macrophages. Here we report the feasibility of applying
fMLP-grafted liposomes as a delivery system for primaquine
against experimental leishmaniasis in animal models.
MATERIALS AND METHODS
Materials. Phosphatidylethanolamine (PE), cholesterol, phosphatidic acid,
fMLP, and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC1)
were purchased from Sigma. RPMI 1640 medium and medium 199 were from
Gibco. All other reagents were of analytical grade.
Peritoneal macrophages were isolated from Swiss albino mice 4 days after the
intraperitoneal injection of 1 ml of sodium thioglycolate (4%). They were cul-
tured in RPMI 1640 medium containing L-glutamine (4 mM), HEPES (25 mM),
streptomycin (100 mg/ml), penicillin (100 U/ml), and 20% fetal bovine serum.
The amastigotes of Leishmania donovani AG83 were maintained in susceptible
golden hamsters. The promastigotes were obtained after 5 days of continuous
culture of the amastigotes in medium 199 containing 20% fetal calf serum,
HEPES (0.15 M), penicillin (100 U/ml), and streptomycin (100 mg/ml). The
bovine serum albumin (BSA) was radioiodinated with chloramine T by the
standard method (10) and was purified from unreacted Na125I by Sephadex G-50
column chromatography.
Preparation of liposomes. The liposomes were prepared by following the
standard procedure (8). In brief, PE, cholesterol, and phosphatidic acid were
placed in a round-bottom flask at a molar ratio of 7:2:1 and were dissolved in
CHCl3-methanol (85:15; vol/vol). The organic solvents were evaporated to dry-
ness in a rotary evaporator under an N2 atmosphere. The dry lipid film was
swelled with 125I-labeled BSA or with the drug for 1 h at 37°C followed by
sonication for 30 s. This suspension was centrifuged in a Beckman ultracentrifuge
(100,000 3 g) for 30 min. The pellet was similarly washed twice and was finally
suspended in 2 ml of phosphate-buffered saline (PBS; pH 7.4).
Grafting of fMLP onto the liposomal surface. The coupling between the
ONH2 group of PE liposomes and the OCOOH group of fMLP was done by
using EDC1 by following the published procedure (5). In brief, the required
amount of fMLP was added dropwise to the liposomal suspension, followed by
the dropwise addition of EDC1. The pH of the solution was maintained at 4.3 to
4.5 with 0.1 N HCl. The reaction was allowed to proceed for 2 h at room
temperature. The suspension was then layered over 7 ml of Ficoll-Paque and was
centrifuged at 750 3 g for 20 min. The liposome suspension floating on top was
taken out and was washed twice by centrifugation at (100,000 3 g) for 30 min. The
pellet finally obtained was suspended in PBS containing 0.1 N CaCl2. The
grafting efficiency was about 50 to 60% with the various amounts of fMLP (see
Fig. 1).
In vitro uptake of peptide-grafted liposomes by macrophages as a function of
both peptide concentration and time. For the uptake study, the fMLP-grafted
liposomes containing 125I-labeled BSA were used. A total of 200 ml of each
liposomal suspension (2 mg of phospholipid) in which various amounts of fMLP
(0 to 150 nmol) were grafted onto the liposomal surface was incubated with the
macrophages (105 cells in 300 ml of RPMI 1640 medium) at 37°C. After 1 h the
suspension was centrifuged (500 3 g for 2 min) and washed twice and the pellet
was taken for counting of the radioactivity.
For studying the dependence of uptake with time, 200 ml of liposomal sus-
pension, both regular and modified with 100 nmol of fMLP grafted onto the
liposomal surface, was incubated with the cells (105 in 300 ml of RPMI 1640
medium) at 37°C for various time periods. At different time intervals, the sus-
pension was centrifuged as described above and washed and the radioactivity was
counted. The nonspecific uptake study was done by preincubating the macro-
phages (105) with a large excess of free fMLP (1 mmol) for 30 min at room
temperature. After 30 min, the cell suspension was centrifuged and washed. The
cell pellet was suspended in 300 ml of RPMI 1640 medium. A total of 200 ml of
the liposomal suspension with 100 nmol of fMLP on the liposomal surface was
added to the cell suspension, and the mixture was incubated at 37°C for various
time periods. At various time intervals the suspension was centrifuged and washed
and the radioactivity was counted. The ungrafted liposomes were used as controls.
The cell protein in all the cases was assayed by the method of Lowry et al. (11).
In vitro parasite killing by the liposomes, free peptide, and primaquine. The
macrophages (105 cells) were incubated with L. donovani promastigotes at a ratio
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of 1:20 for 2 h at 37°C on a coverslip. After 2 h the nonadhering cells were
removed by washing with PBS. These infected macrophages were then incubated
with either 200 ml of free peptide (100 nmol), 200 ml of empty liposomes, or 200
ml of peptide (100 nmol)-grafted empty liposomes in RPMI 1640 medium at
37°C for various time periods. At various time periods, the cover glasses were
removed and their contents were washed with PBS, air dried, and stained with
Giemsa. For each glass the total number of parasites per 300 cells was counted.
The untreated infected macrophages were used as controls. The infected mac-
rophages on the cover glass were also incubated with 200 ml of free primaquine
in RPMI 1640 medium over a certain range of concentrations, washed, stained
with Giemsa, and examined for morphology and internal parasites.
Encapsulation of primaquine within the liposomes. The liposomes were pre-
pared as described above. A certain amount of primaquine was given during
swelling of the lipid film. After 1 h, the suspension was sonicated briefly, centri-
fuged at (100,000 3 g for 30 min), and washed twice. All the washings were
collected, and the amount of primaquine present in the supernatant was deter-
mined by measuring the optical density at 360 nm (ε 5 3,100 M21 cm21). The
level of encapsulation was found to be 14%.
Animal experiment. Our colony of golden hamsters (Mesocricatus auratus),
originally from the Haffkine Research Institute, Bombay, India, was used to
maintain L. donovani AG83 from an Indian patient with kala-azar by intracardial
passage every 6 weeks. Amastigotes were isolated from spleen by the standard
method (12). Each animal was injected with 2 3 106 amastigotes intracardially.
A group of 24 hamsters of average body weight (100 g) was infected at a time and
was ready for drug testing after 30 days. The hamsters (four in each group) were
distributed for drug treatment in the following manner: (i) free primaquine (100
mg/kg of body weight), (ii) empty normal liposomes, (iii) empty peptide-grafted
liposomes, (iv) primaquine encapsulated in ordinary liposomes, (v) primaquine en-
capsulated in peptide-grafted liposomes, and (vi) untreated infected controls.
The amount of primaquine given to each animal was 100 mg/kg of body weight.
For determination of the 50% lethal dose, the single dose subcutaneous treat-
ment was followed by treatment with various amounts of primaquine (40 to 500
mg/kg). The optimum dose was found to be about 100 mg/kg of body weight. For
chemotherapy, a multiple-dose treatment was used. In practice, 10 mg of prima-
quine in 0.5 ml of liposomal suspension containing 6 mg of lipid was injected
subcutaneously into each hamster every 3 days for a total of four doses over 10
days. Free drug (10 mg/0.5 ml of PBS) was also injected similarly. The animals
were killed 3 days after the last injection. Parasite burdens were assessed from
stained impression smears by using the formula of Stauber et al. (20). The
peptide concentration was kept constant (10 mmol/ml) for all liposomal prepa-
rations used for the in vivo experiments.
Investigation of drug toxicity. A few parameters like blood pathology, tissue
histology, and specific enzyme levels related to normal liver function were chosen
to determine the toxic effects of the drugs delivered in both the free and the
liposomal forms. The animals were killed after the drug treatment. The spleens
of the animals were removed for histological examination by eosin and hema-
toxylin staining (9). Blood samples from the animals were assayed for (i) levels of
specific enzymes (e.g., serum glutamate pyruvate transaminase [SGPT] and al-
kaline phosphatase [4]), (ii) the serum bilirubin concentration (17), (iii) blood urea
concentration (14), and (iv) hemoglobin concentration by established procedures.
RESULTS
Uptake of peptide-grafted liposomes as a function of peptide
concentration and time. The saturability of the peptide recep-
tors on the macrophage surface is shown by incubating the
macrophages with increasing amounts of peptide grafted onto
the liposomal surface at 37°C. The saturation occurred with
about 100 nmol of peptide grafted onto the liposome surface
(Fig. 1). The phagocytosis of fMLP-grafted liposomes by mac-
rophages was time dependent and reached equilibrium at
about 30 min. The uptake at 4°C is very low and is independent
of time (data not shown). The process of binding between the
peptide receptors and peptide-grafted liposomes was found to
be specific in nature. Preincubation of the macrophages with
excess free fMLP inhibited further binding, followed by the
internalization of fMLP-grafted liposomes through the peptide
receptors. A nonsignificant decrease in uptake was noticed for
fMLP-grafted liposomes in comparison to that for the regular
liposomes (Fig. 2). The microbicidal activities of fMLP itself
and fMLP-grafted empty liposomes were determined by incu-
bating them separately with L. donovani-infected macrophages
for various time periods. The number of parasites within the
macrophages was markedly reduced within 3 h of incubation
compared to the number of parasites within untreated cells.
The almost similar extent of parasite killing for both the pep-
tide and the peptide-grafted liposomes indicated unaltered
microbicidal activity even after chemical modification. Parasite
killing to the extent of 5 to 8% was also noticed for empty
ungrafted liposomes (Table 1).
FIG. 1. Uptake of peptide-grafted liposomes by macrophages as a function of
peptide concentration. Results are expressed as means 6 standard deviations
(n 5 3).
FIG. 2. Specific uptake of peptide-grafted liposomes by macrophages. Re-
sults are expressed as means 6 standard deviations (n 5 3).
TABLE 1. Microbicidal effect of free peptide, empty liposomes,
and peptide-grafted empty liposomes on L. donovani-infected
macrophages as a function of time (in vitro)
Group
No. of parasites/100 macrophages
(% reduction) at the following timesa:
1 h 2 h 3 h
Control 266 6 12 287 6 20 351 6 59
Free peptide ND ND 218 6 32 (37.6)
Empty liposomes 251 6 6 (5.6) 266 6 7 (7.3) 320 6 20 (8.5)
Peptide-grafted
empty liposomes
231 6 9 (13.5) 207 6 36 (28.4) 201 6 42 (42.7)
a Results are expressed as means 6 standard deviations (n 5 3). For each case,
at least 300 cells were counted. ND, not determined.
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Microbicidal activity and toxicity of peptide-grafted liposo-
mal primaquine. The microbicidal activity of fMLP-grafted
liposomal primaquine in the hamster model of a 30-day
L. donovani infection is shown in Table 2. About 14% of the
drug used for swelling was encapsulated within the liposomes
lmax 5 360 nm; ε 5 3,100 M
21 cm21). With multiple treat-
ments with free drug at a dose of 100 mg/kg of body weight, the
reduction in the spleen parasite load was 17.2%, whereas with
the same type of treatment but with the liposomal drug the
reduction in the spleen parasite load was 50%. The peptide-
grafted empty liposomes and the peptide-grafted liposomal
primaquine reduced the spleen parasite load by 31 and 75%,
respectively. The reduction in the spleen parasite load (10 to
15%) brought about by empty liposomes was probably the
result of an adjuvant effect.
In an attempt to determine the toxicity of the drug and/or
the delivery system itself, the levels of two specific enzymes
(alkaline phosphatase and SGPT), serum bilirubin levels, and
blood urea levels were determined. The results are presented
in Table 3. The activities of both enzymes increased with free
drug treatment but were reduced and became close to the
normal level with treatment with peptide-grafted liposomal
drug. The serum bilirubin level was maximum for the infected
animal, indicating liver blockage by the parasites, but the level
decreased with the reduction in the parasite load with treat-
ment with the peptide-grafted liposomal drug. The almost con-
stant level of urea in blood indicated the absence of any neph-
rotoxicity. The other blood parameters like the erythrocyte
level, the leukocyte level, and the hemoglobin content were
practically unchanged (data not shown). Histological examina-
tion of spleen was also performed after the various treatments.
The sizes or shapes of the white pulp, red pulp, and arteries
after the treatment of the fMLP-grafted liposomal drug were
very close to those of a normal spleen (data not shown), again
indicating reduced toxicity under the given conditions.
DISCUSSION
The reversibility of the binding (at 4°C) between the ligand
and the fMLP receptor on the cell surface has already been
reported (19), but the internalization of the receptor-ligand
complex leads to occasional irreversibility at 37°C. It has been
reported that these receptors are not recycled on the cell
surface during 2 h of incubation (16). The uptake in vitro of the
fMLP-grafted liposomes at 37°C is rapid and highly specific.
The uptake attained equilibrium in about 30 min. This in vitro
specificity of the receptor-ligand interaction was also noticed
when it was tested in vivo. The peptide-grafted liposomes are
found to be rapidly cleared from the blood circulation (half-
life, ;2 min) and taken up by the cells of the reticuloendothe-
lial system. It is known that neutrophils possess the receptor
for the peptides (2, 3, 16), but due to the short circulation time,
the level of uptake of these liposomes by neutrophils is very
low (;1%) compared to that of cells of the reticuloendothelial
system.
The macrophage-activating property of fMLP is well known,
resulting in the production of a series of reactive toxic oxygen
metabolites like OHz, O2
2, and H2O2 (2, 3). These metabolites
are the causative agent of nonspecific killing of various patho-
gens. The in vitro time-dependent killing of the leishmania
parasite within the macrophages demonstrates that the acti-
vating property of fMLP is not affected after the chemical
grafting with the ONH2 group of PE liposomes (Table 1).
The applicability of this delivery system has been tested in
vivo against experimental leishmaniasis in the hamster model
by using primaquine. The mechanism of action of primaquine
is through the production of O2
2 (13, 15). It has been found
that with equivalent drug concentrations, fMLP-grafted lipo-
somes are much more effective than either regular liposomes
or free drug. Interestingly, the empty fMLP-grafted liposomes
reduced the spleen parasite load by 31%, supporting the sup-
position that the peptide-triggered production of O2
2 kills the
microorganisms. Therefore, both the drug alone and the de-
livery system alone are capable of killing parasites through O2
2
production. Enhanced drug activity (Table 2) or reduced drug
toxicity (Table 3) is evidenced in the liposomal or the peptide-
grafted liposomal form.
This study demonstrates that the efficacy of a drug against
reversible leishmaniasis is increased if the drug is used in the
fMLP-grafted liposomal form. Unlike other delivery systems,
the fMLP-grafted liposome is not only capable of delivering
drugs to the macrophages but it also activates the macro-
phage’s respiratory burst, leading to nonspecific killing of
pathogens. It appears that fMLP-grafted or other chemoattrac-
TABLE 2. Effect of peptide-grafted liposomal primaquine on
hamster model of 30-day L. donovani infectiona
Treatment Spleen parasiteload (107)b
% Suppression of
spleen parasite
load
Infected control 9.6 6 4.0
Free drug 7.9 6 0.8 17.0
Liposomal drug 4.9 6 0.5c 49.0
Peptide-grafted empty liposomes 6.9 6 0.8 31.0
Peptide-grafted liposomal drug 2.3 6 0.2c 75.4
a The reduction in the parasite load by empty liposomes was about 10 to 15%.
b Spleen parasite load 5 number of amastigotes per host cell 3 weight of
spleen (in milligrams) 3 (2 3 107). Results are expressed as means 6 standard
deviations (n 5 4).
c P , 0.001 compared to infected control.
TABLE 3. Effect of peptide-grafted liposomal primaquine on specific toxicity parametersa
Group
(treatment)
Alkaline phosphatase level
(mmol of p-nitrophenol
released/min/liter of
serum)
SGPT level (mmol of
sodium pyruvate released/
min/dl of serum)
Serum bilirubin concn
(mmol/liter)
Blood urea concn
(mg/100 ml of
blood)
Normal 8.2 6 2.5 42.0 6 6.0 5.6 6 1.4 14.9 6 3.1
Infected control 16.2 6 2.3 56.5 6 5.6 71.2 6 2.3 11.6 6 2.9
Free drug 23.0 6 3.0 94.8 6 5.8 55.0 6 9.6 13.9 6 1.3
Liposomal drug 19.3 6 2.6 74.9 6 3.6 31.4 6 4.5 11.5 6 1.0
fMLP-grafted empty liposomes 14.2 6 2.2 57.1 6 4.1 40.4 6 4.2 ND
fMLP-grafted liposomal drug 17.3 6 2.7 60.0 6 6.9 7.9 6 3.1 15.3 6 2.0
a Results are expressed as means 6 standard deviations (n 5 4). ND, not determined.
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tant-grafted (1, 7) liposomes would possibly have useful appli-
cations against other macrophage-associated disorders in the
near future.
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